Galenica Future Growth

Future criteria checks 2/6

Galenica is forecast to grow earnings and revenue by 5.3% and 4.2% per annum respectively. EPS is expected to grow by 6% per annum. Return on equity is forecast to be 12% in 3 years.

Key information

5.3%

Earnings growth rate

6.0%

EPS growth rate

Healthcare earnings growth	23.3%
Revenue growth rate	4.2%
Future return on equity	12.0%
Analyst coverage	Low
Last updated	25 Oct 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

LSE:0ROG - Analysts future estimates and past financials data (CHF Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	4,243	190	238	N/A	3
12/31/2025	4,058	180	217	N/A	4
12/31/2024	3,890	172	195	N/A	4
6/30/2024	3,803	170	181	265	N/A
3/31/2024	3,780	167	165	245	N/A
12/31/2023	3,756	165	149	226	N/A
9/30/2023	3,724	158	140	214	N/A
6/30/2023	3,693	152	130	203	N/A
3/31/2023	3,644	154	149	220	N/A
12/31/2022	3,595	157	167	237	N/A
9/30/2022	3,671	162	168	235	N/A
6/30/2022	3,746	167	168	234	N/A
3/31/2022	3,794	167	221	283	N/A
12/31/2021	3,841	168	273	333	N/A
9/30/2021	3,746	177	259	316	N/A
6/30/2021	3,652	185	244	298	N/A
3/31/2021	3,568	179	206	261	N/A
12/31/2020	3,485	172	169	224	N/A
9/30/2020	3,441	149	177	232	N/A
6/30/2020	3,396	126	185	240	N/A
3/31/2020	3,351	126	191	245	N/A
12/31/2019	3,306	125	197	250	N/A
9/30/2019	3,256	140	155	209	N/A
6/30/2019	3,206	156	114	167	N/A
3/31/2019	3,188	152	120	170	N/A
12/31/2018	3,171	148	126	174	N/A
9/30/2018	3,165	132	N/A	N/A	N/A
6/30/2018	3,159	117	115	154	N/A
3/31/2018	3,152	118	N/A	149	N/A
12/31/2017	3,145	119	N/A	144	N/A
9/30/2017	3,112	111	N/A	N/A	N/A
6/30/2017	3,078	104	N/A	195	N/A
3/31/2017	3,057	94	N/A	176	N/A
12/31/2016	3,037	83	N/A	157	N/A
12/31/2015	2,918	81	N/A	132	N/A
12/31/2014	2,829	82	N/A	84	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 0ROG's forecast earnings growth (5.3% per year) is above the savings rate (2.1%).

Earnings vs Market: 0ROG's earnings (5.3% per year) are forecast to grow slower than the UK market (14.6% per year).

High Growth Earnings: 0ROG's earnings are forecast to grow, but not significantly.

Revenue vs Market: 0ROG's revenue (4.2% per year) is forecast to grow faster than the UK market (3.6% per year).

High Growth Revenue: 0ROG's revenue (4.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 0ROG's Return on Equity is forecast to be low in 3 years time (12%).

Galenica Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Recent updates

First half 2024 earnings released: EPS: CHF1.58 (vs CHF1.49 in 1H 2023)

Upcoming dividend of CHF2.20 per share

Full year 2023 earnings released: EPS: CHF3.31 (vs CHF3.15 in FY 2022)

Galenica AG to Report Fiscal Year 2024 Results on Mar 11, 2025

Galenica AG to Report First Half, 2024 Results on Aug 06, 2024

First half 2023 earnings released: EPS: CHF1.49 (vs CHF1.59 in 1H 2022)

New minor risk - Financial position

Now 21% undervalued after recent price drop

Now 20% undervalued after recent price drop

Galenica AG (SWX:GALE) acquired AD Swiss Net AG.

Galenica AG to Report Fiscal Year 2023 Final Results on Mar 12, 2024

Upcoming dividend of CHF2.20 per share at 2.7% yield

Now 23% undervalued

Now 20% undervalued

Bruno sauter acquired Careproduct AG on Galenica AG (SWX:GALE).

First half 2022 earnings released

Galenica AG to Report Q2, 2023 Results on Aug 08, 2023

Galenica AG (SWX:GALE) acquired Aquantic Ltd.

Galenica AG (SWX:GALE) acquired an unknown stake in Well Gesundheit AG.

Galenica AG, Annual General Meeting, May 03, 2023

Upcoming dividend of CHF2.10 per share

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

First half 2021 earnings released: EPS CHF1.60 (vs CHF1.34 in 1H 2020)

Upcoming dividend of CHF1.80 per share

Full year 2020 earnings released: EPS CHF3.48 (vs CHF2.54 in FY 2019)

Revenue beats expectations

New 90-day low: CHF57.90

Galenica AG to Report First Half, 2021 Results on Aug 03, 2021

Biofrontera Pharma GmbH Enters into License and Supply Agreement with Galenica AB for the Marketing of Ameluz in Scandinavia

New 90-day low: CHF57.60

New 90-day low: CHF61.25

New 90-day low - CHF64.50

First half earnings released

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies